RU2753965C2 - Химерные антигенные рецепторы и способы их получения - Google Patents

Химерные антигенные рецепторы и способы их получения Download PDF

Info

Publication number
RU2753965C2
RU2753965C2 RU2016136370A RU2016136370A RU2753965C2 RU 2753965 C2 RU2753965 C2 RU 2753965C2 RU 2016136370 A RU2016136370 A RU 2016136370A RU 2016136370 A RU2016136370 A RU 2016136370A RU 2753965 C2 RU2753965 C2 RU 2753965C2
Authority
RU
Russia
Prior art keywords
cell
car
cells
seq
cd3ζ
Prior art date
Application number
RU2016136370A
Other languages
English (en)
Russian (ru)
Other versions
RU2016136370A3 (enExample
RU2016136370A (ru
Inventor
Лоуренс Дж. Н. КУПЕР
Ана Беатриц КОРНГОЛД
Брайан А. РАБИНОВИЧ
Харджеет СИНГХ
Саймон ОЛИВАРЕС
Original Assignee
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем filed Critical Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Publication of RU2016136370A publication Critical patent/RU2016136370A/ru
Publication of RU2016136370A3 publication Critical patent/RU2016136370A3/ru
Application granted granted Critical
Publication of RU2753965C2 publication Critical patent/RU2753965C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
RU2016136370A 2014-02-14 2015-02-16 Химерные антигенные рецепторы и способы их получения RU2753965C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461940339P 2014-02-14 2014-02-14
US61/940,339 2014-02-14
PCT/US2015/016057 WO2015123642A1 (en) 2014-02-14 2015-02-16 Chimeric antigen receptors and methods of making

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021123419A Division RU2021123419A (ru) 2014-02-14 2015-02-16 Химерные антигенные рецепторы и способы их получения

Publications (3)

Publication Number Publication Date
RU2016136370A RU2016136370A (ru) 2018-09-05
RU2016136370A3 RU2016136370A3 (enExample) 2019-02-21
RU2753965C2 true RU2753965C2 (ru) 2021-08-24

Family

ID=53800695

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016136370A RU2753965C2 (ru) 2014-02-14 2015-02-16 Химерные антигенные рецепторы и способы их получения
RU2021123419A RU2021123419A (ru) 2014-02-14 2015-02-16 Химерные антигенные рецепторы и способы их получения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021123419A RU2021123419A (ru) 2014-02-14 2015-02-16 Химерные антигенные рецепторы и способы их получения

Country Status (15)

Country Link
US (4) US10125193B2 (enExample)
EP (2) EP3105335B1 (enExample)
JP (2) JP6640726B2 (enExample)
KR (1) KR102375998B1 (enExample)
CN (2) CN106414748B (enExample)
AU (2) AU2015218239B2 (enExample)
CA (2) CA2938887C (enExample)
DK (1) DK3105335T3 (enExample)
ES (1) ES2764471T3 (enExample)
IL (3) IL247208B (enExample)
MX (2) MX369513B (enExample)
RU (2) RU2753965C2 (enExample)
SG (2) SG11201606664UA (enExample)
WO (1) WO2015123642A1 (enExample)
ZA (2) ZA201605655B (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN106414748B (zh) * 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
PH12016502010B1 (en) 2014-04-10 2023-08-16 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Drug related transgene expression
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
KR102624023B1 (ko) 2015-02-24 2024-01-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 결합-촉발된 전사 스위치 및 이들의 이용 방법
CA2976126A1 (en) 2015-02-24 2016-09-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified t cells
MX388517B (es) 2015-03-11 2025-03-19 Univ Texas Polipéptidos de transposasa y sus usos.
US9777064B2 (en) 2015-03-17 2017-10-03 Chimera Bioengineering, Inc. Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
WO2016172372A1 (en) * 2015-04-23 2016-10-27 Baylor College Of Medicine Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
SG10201914069SA (en) 2015-05-18 2020-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
US11116795B2 (en) * 2015-07-10 2021-09-14 The Trustees Of The University Of Pennsylvania Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
PT3344803T (pt) 2015-09-01 2021-09-20 Univ California Bibliotecas de polipéptidos modulares e métodos de produção e utilização das mesmas
HK1258218A1 (zh) 2015-09-15 2019-11-08 Board Of Regents, The University Of Texas System T細胞受體(tcr)結合抗體及其應用
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
WO2017193059A1 (en) * 2016-05-06 2017-11-09 The Regents Of The University Of California Systems and methods for targeting cancer cells
US10222369B2 (en) 2016-05-17 2019-03-05 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
IL321834A (en) 2016-06-08 2025-08-01 Precigen Inc Cd33 specific chimeric antigen receptors
CN106167527A (zh) * 2016-06-13 2016-11-30 长沙郝怡雅医药科技有限公司 一种融合蛋白
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
EP3714944A1 (en) 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
JP7500195B2 (ja) 2016-08-23 2024-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
WO2018045177A1 (en) 2016-09-01 2018-03-08 Chimera Bioengineering, Inc. Gold optimized car t-cells
MX389789B (es) * 2016-09-27 2025-03-20 Cero Therapeutics Inc Moléculas del receptor de envolvimiento quimérico.
US20190119636A1 (en) * 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3848392A1 (en) 2016-10-07 2021-07-14 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR20240057444A (ko) 2017-03-27 2024-05-02 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN107177632B (zh) * 2017-05-27 2020-02-07 上海优卡迪生物医药科技有限公司 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用
CN110997920A (zh) 2017-06-07 2020-04-10 英特拉克森公司 新型细胞标签的表达
CN109337872B (zh) * 2017-07-27 2023-06-23 上海细胞治疗研究院 高效扩增car-t细胞的人工抗原递呈细胞及其用途
CN107529550A (zh) * 2017-08-28 2018-01-02 马晓冬 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法
CA3072777A1 (en) * 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
AU2018331517B2 (en) * 2017-09-15 2024-10-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
AU2018341244A1 (en) * 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
EA202090757A1 (ru) * 2017-09-29 2020-08-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
KR102742741B1 (ko) * 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
US10329543B2 (en) * 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
FI3703710T3 (fi) * 2017-10-31 2024-10-09 Allogene Therapeutics Inc Menetelmiä ja koostumuksia allogeenisten kimeeristä antigeenireseptoria kantavien t-solujen annostelemiseksi refraktorisen ja/tai uusiutuneen suurisoluisen b-solulymfooman tai refraktorisen ja/tai uusiutuneen follikulaarisen lymfooman hoitamista varten
WO2019090110A1 (en) 2017-11-03 2019-05-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ror1 immunotherapy
EP4083192A1 (en) 2017-12-22 2022-11-02 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
CN109970864A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 一种双向激活共刺激分子受体及其用途
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3806870A4 (en) 2018-02-13 2021-12-22 Chimera Bioengineering, Inc. COORDINATION OF GENE EXPRESSION USING RNA DESSTABILIZATION ELEMENTS
WO2019178518A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
WO2019191334A1 (en) * 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2019191340A1 (en) * 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
JP7575271B2 (ja) 2018-03-29 2024-10-29 フェイト セラピューティクス，インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN110577605A (zh) * 2018-06-11 2019-12-17 浙江启新生物技术有限公司 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
SG11202105480WA (en) 2018-12-02 2021-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
CN111253487B (zh) * 2018-12-03 2024-02-02 广东东阳光药业股份有限公司 Cd19抗体及其应用
CN120025452A (zh) 2018-12-12 2025-05-23 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
CN109777784B (zh) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
CA3131533A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020209934A1 (en) * 2019-04-11 2020-10-15 Massachusetts Institute Of Technology Novel chimeric antigen receptors and libraries
WO2021034653A1 (en) 2019-08-18 2021-02-25 Chimera Bioengineering, Inc. Combination therapy with gold controlled transgenes
GB2628935B (en) 2019-09-03 2025-03-05 Myeloid Therapeutics Inc Methods and compositions for genomic integration
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
GB201915384D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Vector
CN110964750A (zh) * 2019-11-13 2020-04-07 沣潮医药科技（上海）有限公司 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途
CN111304244A (zh) * 2019-11-13 2020-06-19 沣潮医药科技（上海）有限公司 携带基因元件组合的载体组件、受体细胞文库、制备和筛选方法及用途
US20230073449A1 (en) 2020-01-23 2023-03-09 The Children's Medical Center Corporation Stroma-free t cell differentiation from human pluripotent stem cells
EP4118191A1 (en) 2020-04-23 2023-01-18 The Regents Of The University Of California Genetically engineered phagocytes, and related compositions, vectors, methods and systems
CN115715295A (zh) 2020-05-27 2023-02-24 安逊生物科学股份有限公司 将car t细胞重新定向到感兴趣的抗原的衔接分子
GB202008688D0 (en) * 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
MX2022015863A (es) 2020-06-19 2023-03-23 Fate Therapeutics Inc Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia.
CN113913458A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 非病毒方法制备稳定高表达嵌合受体的nk细胞
CN112062859B (zh) * 2020-07-24 2022-08-09 沣潮医药科技（上海）有限公司 用于病原体清除的嵌合抗原受体及其应用
EP4281566A1 (en) 2021-01-20 2023-11-29 Coding Bio Limited Methods for high throughput screening of chimeric antigen receptors
CA3215938A1 (en) * 2021-04-23 2022-10-27 Henry Hongjun Ji Dimeric antigen receptors (dars) that bind gd2
JP2024518100A (ja) 2021-05-11 2024-04-24 マイエロイド・セラピューティクス，インコーポレーテッド ゲノム組込みのための方法および組成物
US20250136689A1 (en) * 2022-02-04 2025-05-01 Duke University Compositions for and methods of treating hematological cancers
WO2023150674A2 (en) * 2022-02-04 2023-08-10 Duke University Compositions for and methods of effecting tumor cell death
JP7707304B2 (ja) 2022-04-08 2025-07-14 フェイト セラピューティクス，インコーポレイティド 腫瘍標的化のためのキメラ抗原受容体
JP7701453B2 (ja) 2022-04-08 2025-07-01 フェイト セラピューティクス，インコーポレイティド 固形腫瘍標的化骨格を有する細胞及びその使用
JPWO2024150828A1 (enExample) * 2023-01-12 2024-07-18

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013176915A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
ATE240119T1 (de) 1995-03-08 2003-05-15 Scripps Research Inst Antigen präsentierendes system und aktivierung von t-zellen
AU723355B2 (en) 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
JP2002511741A (ja) 1997-03-11 2002-04-16 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム
WO1998042838A1 (en) 1997-03-25 1998-10-01 Morphogenesis, Inc. Universal stem cells
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
CA2425862C (en) 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
AU2002256390B2 (en) 2001-04-30 2007-08-30 City Of Hope Chimeric immunoreceptor useful in treating human cancers
JPWO2003066677A1 (ja) 2002-02-05 2005-05-26 独立行政法人科学技術振興機構 Ｅｇｆ／ｅｇｆｒ複合体
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2004067779A2 (en) 2003-01-30 2004-08-12 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20070066802A1 (en) * 2003-08-20 2007-03-22 Geiger Terrance L Chimeric receptors with disrupted dileucine motifs
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CA2590401C (en) 2004-10-08 2015-04-21 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Adoptive immunotherapy with enhanced t lymphocyte survival
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
CA2643337C (en) 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
WO2007138098A2 (en) 2006-05-31 2007-12-06 Projech Science To Technology, S.L. Animal models of tumour metastasis and toxicity
RU2355763C2 (ru) 2006-09-13 2009-05-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот
AU2007307206B2 (en) 2006-10-04 2016-02-11 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
CN101573380A (zh) * 2006-10-12 2009-11-04 健泰科生物技术公司 针对淋巴毒素-α的抗体
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US9931377B2 (en) 2007-06-27 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell expressing complexes of IL-15 and IL-15Ralpha
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US20100105140A1 (en) 2008-07-16 2010-04-29 Fahrenkrug Scott C Plaice dna transposon system
WO2010030947A1 (en) 2008-09-11 2010-03-18 University Of Florida Research Foundation, Inc. System and method for producing t cells
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP2596011B1 (en) 2010-07-21 2018-10-03 Sangamo Therapeutics, Inc. Methods and compositions for modification of a hla locus
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) * 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
EA201490636A1 (ru) 2011-09-16 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
IN2014CN02906A (enExample) 2011-10-20 2015-07-03 Us Health
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
SG11201402783YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
BR112014020499A2 (pt) * 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, célula - t, vetor, e, população persistente de células - t
EP4230647A1 (en) * 2012-02-22 2023-08-23 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
KR20210032014A (ko) 2012-04-11 2021-03-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
WO2014037807A2 (en) 2012-09-07 2014-03-13 Biolamina Ab Stem cell bank
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014164554A1 (en) 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015061694A2 (en) 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
CN106414748B (zh) * 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
CN106459924A (zh) 2014-04-23 2017-02-22 得克萨斯州大学系统董事会 用于疗法中的嵌合抗原受体(car)及其制备方法
CA2945393C (en) 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
JP6655061B2 (ja) 2014-07-29 2020-02-26 ノバルティス アーゲー 状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2976126A1 (en) 2015-02-24 2016-09-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified t cells
MX388517B (es) 2015-03-11 2025-03-19 Univ Texas Polipéptidos de transposasa y sus usos.
HK1258218A1 (zh) 2015-09-15 2019-11-08 Board Of Regents, The University Of Texas System T細胞受體(tcr)結合抗體及其應用
KR20180125435A (ko) 2015-09-25 2018-11-23 알토 바이오사이언스 코포레이션 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017177063A1 (en) 2016-04-06 2017-10-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of heterodimeric il-15 in adoptive cell transfer
CN118406655A (zh) * 2017-01-10 2024-07-30 普瑞赛格恩公司 通过新基因开关表达系统调节多肽的表达

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013176915A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIN Z. et al., The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor, Gene Therapy, 2011, V. 18, N.9, p.849-856. *
КОРЖ В.П., ПОИСК ТКАНЕСПЕЦИФИЧНЫХ РЕГУЛЯТОРНЫХ ЭЛЕМЕНТОВ С ПОМОЩЬЮ ТРАНСПОЗОНА Tol2 КАК ПРИМЕР ЭВОЛЮЦИОННОГО СИНТЕЗА ГЕНОМИКИ И БИОЛОГИИ РАЗВИТИЯ, ОНТОГЕНЕЗ, 2008, V.39, N.2, с.94-99. *
ЛИКАРЬ Ю. Н. и др., Использование мутированного варианта человеческой деоксицитидинкиназы в качестве репортерного гена для оценки адоптивной Т-клеточной терапии, Вопросы гематологии, онкологии и иммунопатологии в педиатрии, 2012, V. 11, N. 2, c.23-31. *
ЛИКАРЬ Ю. Н. и др., Использование мутированного варианта человеческой деоксицитидинкиназы в качестве репортерного гена для оценки адоптивной Т-клеточной терапии, Вопросы гематологии, онкологии и иммунопатологии в педиатрии, 2012, V. 11, N. 2, c.23-31. КОРЖ В.П., ПОИСК ТКАНЕСПЕЦИФИЧНЫХ РЕГУЛЯТОРНЫХ ЭЛЕМЕНТОВ С ПОМОЩЬЮ ТРАНСПОЗОНА Tol2 КАК ПРИМЕР ЭВОЛЮЦИОННОГО СИНТЕЗА ГЕНОМИКИ И БИОЛОГИИ РАЗВИТИЯ, ОНТОГЕНЕЗ, 2008, V.39, N.2, с.94-99. JIN Z. et al., The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor, Gene Therapy, 2011, V. 18, N.9, p.849-856. *

Also Published As

Publication number Publication date
JP2020058380A (ja) 2020-04-16
AU2019202514A1 (en) 2019-05-02
US12065490B2 (en) 2024-08-20
IL247208B (en) 2020-02-27
MX2019009295A (es) 2019-12-02
AU2015218239B2 (en) 2019-01-31
SG11201606664UA (en) 2016-09-29
DK3105335T3 (da) 2020-01-13
AU2019202514B2 (en) 2022-03-24
MX2016010566A (es) 2017-05-25
US20250002579A1 (en) 2025-01-02
US20210324071A1 (en) 2021-10-21
JP2017506513A (ja) 2017-03-09
IL281819B2 (en) 2023-05-01
WO2015123642A1 (en) 2015-08-20
RU2021123419A (ru) 2021-10-22
MX369513B (es) 2019-11-11
CA2938887C (en) 2023-04-11
CN113234757B (zh) 2024-10-29
IL247208A0 (en) 2016-09-29
US10125193B2 (en) 2018-11-13
ZA201807750B (en) 2024-10-30
ES2764471T3 (es) 2020-06-03
IL281819A (en) 2021-05-31
KR102375998B1 (ko) 2022-03-21
US20190085079A1 (en) 2019-03-21
SG10201811816RA (en) 2019-02-27
EP3105335A1 (en) 2016-12-21
EP3656864A1 (en) 2020-05-27
ZA201605655B (en) 2019-03-27
EP3105335A4 (en) 2017-12-27
US20170183407A1 (en) 2017-06-29
EP3105335B1 (en) 2019-10-02
RU2016136370A3 (enExample) 2019-02-21
IL272264A (en) 2020-02-27
CN106414748B (zh) 2021-05-28
KR20160120307A (ko) 2016-10-17
CA3190002A1 (en) 2015-08-20
CA2938887A1 (en) 2015-08-20
IL272264B (en) 2021-04-29
CN113234757A (zh) 2021-08-10
JP6640726B2 (ja) 2020-02-05
RU2016136370A (ru) 2018-09-05
IL281819B1 (en) 2023-01-01
CN106414748A (zh) 2017-02-15
AU2015218239A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
AU2019202514B2 (en) Chimeric antigen receptors and methods of making
JP7757343B2 (ja) 改変ｔ細胞に関する方法および組成物
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
JP2023052446A (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
EP3368075B1 (en) Chimeric antigen receptor molecules and uses thereof
CN114746438A (zh) 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂
KR20200089285A (ko) Bcma-표적화 키메라 항원 수용체, cd19-표적화 키메라 항원 수용체, 및 병용 요법
JP2018515123A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CN114729059A (zh) 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法
KR20220004076A (ko) 리툭시맙-내성 키메라 항원 수용체 및 이의 용도
RU2816370C2 (ru) Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения
HK40030175A (en) Chimeric antigen receptors and methods of making
EP4626473A1 (en) Humanized anti-hla-g chimeric antigen receptors and uses thereof
CN120265660A (zh) 新型cd19靶向多肽和cd19定向免疫疗法
HK1232561B (en) Chimeric antigen receptors and methods of making
HK1232561A1 (en) Chimeric antigen receptors and methods of making

Legal Events

Date Code Title Description
TK49 Information related to patent modified